- Urine
- Saliva
- Hair
- Blood
- Others
Drug Abuse Testing (DAT) Market size is valued at USD 2,507.4 million in 2023 and is expected to reach USD 3,307.3 million by 2029, at a CAGR of 3.9% from 2024-2030. The workforce drug testing and drug abuse cases mainly drive the drug abuse testing market. The growth of the drug abuse testing (DAT) market is attributed to the increase in usage of alcohol, cannabinoids, cocaine, amphetamines, opiates, and other illicit drugs in various countries across the globe.
The top five drug classes are amphetamines, opiates, alcohol, cocaine, and cannabis, accounting for an 80.8% market share in the global drug abuse testing (DAT) market. The urine sample is highly preferred for initial screening and confirmation. However, the adoption of saliva samples for screening is expected to create lucrative opportunities over the future years due to the manipulation or adulteration of urine samples with synthetic urine by drug abusers. Forensic laboratories prefer hair samples, which may be given for substances abused 90 days back. However, if the person has no hair or short hair, forensic laboratories prefer a nail test. For the majority of urine and saliva samples, immunoassay and onsite testing are highly preferred for initial screening, and positive samples should be confirmed by mass spectrometry.
Drug Abuse Testing (DAT) Market Key Developments:
- In Sept 2019, A new distribution contract was signed by Psychemedics Corporation with Toxicologia Pardini Ltda. and Sanso Holding S.A. in Brazil. Toxicologia Pardini and Sanso was chosen as the Brazilian distributor for Psychemedics' hair drug testing services under the terms of the new deal.
Drug Abuse Testing Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
3.9%
Largest Market
North-America
Fastest Growing Market
North America
Drug Abuse Testing (DAT) Market Dynamics
A growing number of drug users across the globe is responsible for the growth of the drug abuse testing market. The increase in the consumption of alcohol and other illicit drugs such as cannabis, cocaine, heroin, and opiates is a major factor in the growth of the global drug abuse testing market over the forecast years. For instance, according to UNODC 2021, approximately 296 Million people had used drugs per year. However, the number of drugs is gradually increasing due to the rapid growth in population, and unemployment is contributing to drug abuse testing growth around the world. Cannabis is a highly used illicit drug, with an estimated approximately 219 Million people per year around the world. In 2021, approximately 36 Million used amphetamines, 22 million used cocaine, and 20 million used ecstasy. In addition, according to UNODC 2021 data, opioids contribute to drug-related harm that includes fatal overdoses. Around 60 million people engaged in non-medical opioid use in 2021, and 31.5 million used mainly opiates (heroin).
North-America Got Significant Share of
Drug Abuse Testing (DAT) Market Regional Analysis
The North American drug abuse testing (DAT) market dominates with a 56% market share in terms of the number of tests, followed by Europe and Asia Pacific. In the European region, the UK carries out more than 16 million drug abuse tests every year. In terms of the market value, the USA Drug abuse testing market was valued at USD 1,297.3 million in 2023 and projected to reach USD 1,598.0 million by 2029.
In the United States (USA), amphetamines dominated the drug abuse testing (DAT) market in 2023 with an approximate share of 20%, followed by Opiates with 18%, Alcohol Abuse with 15%, and Cannabinoids with 14% share.
Among all the amphetamines, Methamphetamine was the most frequently identified drug, followed by Amphetamine, N-ethylpentylone, and MDMA. Amphetamine abuse is increasing in the USA due to a surge in the number of Amphetamine prescriptions for certain diseases such as obesity, narcolepsy, or attention deficit hyperactivity disorder (ADHD).
Opiates contributed the second largest share in the USA. Opioid abuse increased till 2016 due to a surge in the adoption of prescription pain relievers such as hydrocodone, oxycodone, oxymorphone, morphine, codeine, fentanyl, and others, which are widely prescribed for moderate to severe pain.
Latin America
Europe
Asia Pacific
Middle East
North America
Drug Abuse Testing Market Segmentation
By Sample
By Technology
- Immunoassay
- Onsite Testing
- Mass Spectrometry
- Others
By Geography
- Amphetamines
- Barbiturates
- Cannabinoids
- Cocaine
- Alcohol Abuse
- Heroin Substitution Panel
- LSD
- Designer Drugs
- Benzodiazepines
- Opiates
- Antidepressants
Frequently Asked Questions
Every year, approximately 222 Million drug abuse tests take place across the globe.
Abbott Laboratories, Danaher Corporation (Beckman Coulter), LabCorp, Dragerwerk AG & Co. KGaA, Quest Diagnostics Inc.
North America is the fastest-growing region for Drug Abuse Testing Market
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Drug Abuse Testing Market Introduction |
| 2.1. Global Drug Abuse Testing Market – Taxonomy |
| 2.1.1. Drug Class Type |
| 2.1.2. Sample Type |
| 2.1.3. Technology |
| 2.1.4. Region |
| 3. Global Drug Abuse Testing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Drug Abuse Testing Market – Competition Landscape |
| 4. Global Drug Abuse Testing Market Snapshot, 2023 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2029 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. USA Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 5.1. Volume Breakdown by Sample Type – 2023 |
| 5.1.1. Urine |
| 5.1.2. Saliva |
| 5.1.3. Hair |
| 5.1.4. Blood |
| 5.1.5. Others |
| 5.2. Volume Breakdown by Technology – 2023 |
| 5.2.1. Immunoassay |
| 5.2.2. Onsite Testing |
| 5.2.3. Mass Spectrometry |
| 5.2.4. Others |
| 5.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 5.3.1. Amphetamines |
| 5.3.2. Barbiturates |
| 5.3.3. Cannabinoids |
| 5.3.4. Cocaine |
| 5.3.5. Alcohol Abuse |
| 5.3.6. Heroin Substitution Panel |
| 5.3.7. LSD |
| 5.3.8. Designer Drugs |
| 5.3.9. Benzodiazepines |
| 5.3.10. Opiates |
| 5.3.11. Antidepressants |
| 6. Canada Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 6.1. Volume Breakdown by Sample Type – 2023 |
| 6.1.1. Urine |
| 6.1.2. Saliva |
| 6.1.3. Hair |
| 6.1.4. Blood |
| 6.1.5. Others |
| 6.2. Volume Breakdown by Technology – 2023 |
| 6.2.1. Immunoassay |
| 6.2.2. Onsite Testing |
| 6.2.3. Mass Spectrometry |
| 6.2.4. Others |
| 6.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 6.3.1. Amphetamines |
| 6.3.2. Barbiturates |
| 6.3.3. Cannabinoids |
| 6.3.4. Cocaine |
| 6.3.5. Alcohol Abuse |
| 6.3.6. Heroin Substitution Panel |
| 6.3.7. LSD |
| 6.3.8. Designer Drugs |
| 6.3.9. Benzodiazepines |
| 6.3.10. Opiates |
| 6.3.11. Antidepressants |
| 7. Germany Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 7.1. Volume Breakdown by Sample Type – 2023 |
| 7.1.1. Urine |
| 7.1.2. Saliva |
| 7.1.3. Hair |
| 7.1.4. Blood |
| 7.1.5. Others |
| 7.2. Volume Breakdown by Technology – 2023 |
| 7.2.1. Immunoassay |
| 7.2.2. Onsite Testing |
| 7.2.3. Mass Spectrometry |
| 7.2.4. Others |
| 7.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 7.3.1. Amphetamines |
| 7.3.2. Barbiturates |
| 7.3.3. Cannabinoids |
| 7.3.4. Cocaine |
| 7.3.5. Alcohol Abuse |
| 7.3.6. Heroin Substitution Panel |
| 7.3.7. LSD |
| 7.3.8. Designer Drugs |
| 7.3.9. Benzodiazepines |
| 7.3.10. Opiates |
| 7.3.11. Antidepressants |
| 8. France Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 8.1. Volume Breakdown by Sample Type – 2023 |
| 8.1.1. Urine |
| 8.1.2. Saliva |
| 8.1.3. Hair |
| 8.1.4. Blood |
| 8.1.5. Others |
| 8.2. Volume Breakdown by Technology – 2023 |
| 8.2.1. Immunoassay |
| 8.2.2. Onsite Testing |
| 8.2.3. Mass Spectrometry |
| 8.2.4. Others |
| 8.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 8.3.1. Amphetamines |
| 8.3.2. Barbiturates |
| 8.3.3. Cannabinoids |
| 8.3.4. Cocaine |
| 8.3.5. Alcohol Abuse |
| 8.3.6. Heroin Substitution Panel |
| 8.3.7. LSD |
| 8.3.8. Designer Drugs |
| 8.3.9. Benzodiazepines |
| 8.3.10. Opiates |
| 8.3.11. Antidepressants |
| 9. UK Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 9.1. Volume Breakdown by Sample Type – 2023 |
| 9.1.1. Urine |
| 9.1.2. Saliva |
| 9.1.3. Hair |
| 9.1.4. Blood |
| 9.1.5. Others |
| 9.2. Volume Breakdown by Technology – 2023 |
| 9.2.1. Immunoassay |
| 9.2.2. Onsite Testing |
| 9.2.3. Mass Spectrometry |
| 9.2.4. Others |
| 9.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 9.3.1. Amphetamines |
| 9.3.2. Barbiturates |
| 9.3.3. Cannabinoids |
| 9.3.4. Cocaine |
| 9.3.5. Alcohol Abuse |
| 9.3.6. Heroin Substitution Panel |
| 9.3.7. LSD |
| 9.3.8. Designer Drugs |
| 9.3.9. Benzodiazepines |
| 9.3.10. Opiates |
| 9.3.11. Antidepressants |
| 9.3.12. Methaqualone |
| 10. Italy Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 10.1. Volume Breakdown by Sample Type – 2023 |
| 10.1.1. Urine |
| 10.1.2. Saliva |
| 10.1.3. Hair |
| 10.1.4. Blood |
| 10.1.5. Others |
| 10.2. Volume Breakdown by Technology – 2023 |
| 10.2.1. Immunoassay |
| 10.2.2. Onsite Testing |
| 10.2.3. Mass Spectrometry |
| 10.2.4. Others |
| 10.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 10.3.1. Amphetamines |
| 10.3.2. Cannabinoids |
| 10.3.3. Cocaine |
| 10.3.4. Alcohol Abuse |
| 10.3.5. Heroin Substitution Panel |
| 10.3.6. Benzodiazepines |
| 10.3.7. Opiates |
| 10.3.8. Antidepressants |
| 11. Spain Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 11.1. Volume Breakdown by Sample Type – 2023 |
| 11.1.1. Urine |
| 11.1.2. Saliva |
| 11.1.3. Hair |
| 11.1.4. Blood |
| 11.1.5. Others |
| 11.2. Volume Breakdown by Technology – 2023 |
| 11.2.1. Immunoassay |
| 11.2.2. Onsite Testing |
| 11.2.3. Mass Spectrometry |
| 11.2.4. Others |
| 11.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 11.3.1. Amphetamines |
| 11.3.2. Barbiturates |
| 11.3.3. Cannabinoids |
| 11.3.4. Cocaine |
| 11.3.5. Alcohol Abuse |
| 11.3.6. Heroin Substitution Panel |
| 11.3.7. LSD |
| 11.3.8. Designer Drugs |
| 11.3.9. Benzodiazepines |
| 11.3.10. Opiates |
| 11.3.11. Antidepressants |
| 12. Switzerland Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 12.1. Volume Breakdown by Sample Type – 2023 |
| 12.1.1. Urine |
| 12.1.2. Saliva |
| 12.1.3. Hair |
| 12.1.4. Blood |
| 12.1.5. Others |
| 12.2. Volume Breakdown by Technology – 2023 |
| 12.2.1. Immunoassay |
| 12.2.2. Onsite Testing |
| 12.2.3. Mass Spectrometry |
| 12.2.4. Others |
| 12.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 12.3.1. Amphetamines |
| 12.3.2. Barbiturates |
| 12.3.3. Cannabinoids |
| 12.3.4. Cocaine |
| 12.3.5. Alcohol Abuse |
| 12.3.6. Heroin Substitution Panel |
| 12.3.7. LSD |
| 12.3.8. Designer Drugs |
| 12.3.9. Benzodiazepines |
| 12.3.10. Opiates |
| 12.3.11. Antidepressants |
| 13. Austria Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 13.1. Volume Breakdown by Sample Type – 2023 |
| 13.1.1. Urine |
| 13.1.2. Saliva |
| 13.1.3. Hair |
| 13.1.4. Blood |
| 13.1.5. Others |
| 13.2. Volume Breakdown by Technology – 2023 |
| 13.2.1. Immunoassay |
| 13.2.2. Onsite Testing |
| 13.2.3. Mass Spectrometry |
| 13.2.4. Others |
| 13.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 13.3.1. Amphetamines |
| 13.3.2. Barbiturates |
| 13.3.3. Cannabinoids |
| 13.3.4. Cocaine |
| 13.3.5. Alcohol Abuse |
| 13.3.6. Heroin Substitution Panel |
| 13.3.7. LSD |
| 13.3.8. Designer Drugs |
| 13.3.9. Benzodiazepines |
| 13.3.10. Opiates |
| 13.3.11. Antidepressants |
| 14. China Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 14.1. Volume Breakdown by Sample Type – 2023 |
| 14.1.1. Urine |
| 14.1.2. Saliva |
| 14.1.3. Hair |
| 14.1.4. Blood |
| 14.1.5. Others |
| 14.2. Volume Breakdown by Technology – 2023 |
| 14.2.1. Immunoassay |
| 14.2.2. Onsite Testing |
| 14.2.3. Mass Spectrometry |
| 14.2.4. Others |
| 14.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 14.3.1. Amphetamines |
| 14.3.2. Barbiturates |
| 14.3.3. Cannabinoids |
| 14.3.4. Cocaine |
| 14.3.5. Alcohol Abuse |
| 14.3.6. Heroin Substitution Panel |
| 14.3.7. LSD |
| 14.3.8. Designer Drugs |
| 14.3.9. Benzodiazepines |
| 14.3.10. Opiates |
| 14.3.11. Antidepressants |
| 15. Korea Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 15.1. Volume Breakdown by Sample Type – 2023 |
| 15.1.1. Urine |
| 15.1.2. Saliva |
| 15.1.3. Hair |
| 15.1.4. Blood |
| 15.1.5. Others |
| 15.2. Volume Breakdown by Technology – 2023 |
| 15.2.1. Immunoassay |
| 15.2.2. Onsite Testing |
| 15.2.3. Mass Spectrometry |
| 15.2.4. Others |
| 15.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 15.3.1. Amphetamines |
| 15.3.2. Barbiturates |
| 15.3.3. Cannabinoids |
| 15.3.4. Cocaine |
| 15.3.5. Alcohol Abuse |
| 15.3.6. Heroin Substitution Panel |
| 15.3.7. LSD |
| 15.3.8. Designer Drugs |
| 15.3.9. Benzodiazepines |
| 15.3.10. Opiates |
| 15.3.11. Antidepressants |
| 16. Australia Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 16.1. Volume Breakdown by Sample Type – 2023 |
| 16.1.1. Urine |
| 16.1.2. Saliva |
| 16.1.3. Hair |
| 16.1.4. Blood |
| 16.1.5. Others |
| 16.2. Volume Breakdown by Technology – 2023 |
| 16.2.1. Immunoassay |
| 16.2.2. Onsite Testing |
| 16.2.3. Mass Spectrometry |
| 16.2.4. Others |
| 16.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 16.3.1. Amphetamines |
| 16.3.2. Cannabinoids |
| 16.3.3. Cocaine |
| 16.3.4. Alcohol Abuse |
| 16.3.5. Heroin Substitution Panel |
| 16.3.6. Designer Drugs |
| 16.3.7. Benzodiazepines |
| 16.3.8. Opiates |
| 16.3.9. Antidepressants |
| 17. Brazil Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 17.1. Volume Breakdown by Sample Type – 2023 |
| 17.1.1. Urine |
| 17.1.2. Saliva |
| 17.1.3. Hair |
| 17.1.4. Blood |
| 17.1.5. Others |
| 17.2. Volume Breakdown by Technology – 2023 |
| 17.2.1. Immunoassay |
| 17.2.2. Onsite Testing |
| 17.2.3. Mass Spectrometry |
| 17.2.4. Others |
| 17.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 17.3.1. Amphetamines |
| 17.3.2. Barbiturates |
| 17.3.3. Cannabinoids |
| 17.3.4. Cocaine |
| 17.3.5. Alcohol Abuse |
| 17.3.6. Heroin Substitution Panel |
| 17.3.7. Designer Drugs |
| 17.3.8. Benzodiazepines |
| 17.3.9. Opiates |
| 17.3.10. Antidepressants |
| 18. Central America Drug Abuse Testing Market, 2019 - 2023 and Forecast, 2024 - 2029 (Volume and Value) |
| 18.1. Volume Breakdown by Sample Type – 2023 |
| 18.1.1. Urine |
| 18.1.2. Saliva |
| 18.1.3. Hair |
| 18.1.4. Blood |
| 18.1.5. Others |
| 18.2. Volume Breakdown by Technology – 2023 |
| 18.2.1. Immunoassay |
| 18.2.2. Onsite Testing |
| 18.2.3. Mass Spectrometry |
| 18.2.4. Others |
| 18.3. Drug Abuse Testing Market - 2023, by Drug Class, Market Volume (‘000 Tests) and Market Value (‘000 US$) |
| 18.3.1. Amphetamines |
| 18.3.2. Barbiturates |
| 18.3.3. Cannabinoids |
| 18.3.4. Cocaine |
| 18.3.5. Alcohol Abuse |
| 18.3.6. Heroin Substitution Panel |
| 18.3.7. LSD |
| 18.3.8. Designer Drugs |
| 18.3.9. Benzodiazepines |
| 18.3.10. Opiates |
| 18.3.11. Antidepressants |
| 19. Competition Landscape |
| 19.1. Accuquik Test Kits |
| 19.2. Advin Biotech |
| 19.3. Alere, Inc. (Abbott) |
| 19.4. Alfa Scientific Designs, Inc. |
| 19.5. Andatech |
| 19.6. ARK Diagnostics |
| 19.7. Biopanda Reagents |
| 19.8. Beckman Coulter |
| 19.9. BTNX, Inc. |
| 19.10. Corolina Liquid Chemistries |
| 19.11. Chromsystems, Inc. |
| 19.12. Co-Innovation Biotech Co., Ltd. |
| 19.13. Confirm Biosciences |
| 19.14. Diagnostic Automation/Cortez Diagnostics Inc. |
| 19.15. Diasystems Scandinevia AB |
| 19.16. Germaine Laboratories, Inc. |
| 19.17. Innovative Testing Solution |
| 19.18. Immunostics, Inc. |
| 19.19. Medacx Ltd. |
| 19.20. Meridian Healthcare srl |
| 19.21. Mossman Associates |
| 19.22. Neogen Corporation |
| 19.23. Orasure Technologies, Inc. |
| 19.24. Pharmatech, Inc. |
| 19.25. Premier Biotech |
| 19.26. Prospectol |
| 19.27. Sekisui Diagnostics |
| 19.28. Siemens Healthineers |
| 19.29. Thermo Fisher Scientific, Inc. |
| 20. Research Methodology |
| 21. Appendix and Abbreviations |
- Accuquik Test Kits
- Advin Biotech
- Alere, Inc. (Abbott)
- Alfa Scientific Designs, Inc.
- Andatech
- ARK Diagnostics
- Biopanda Reagents
- Beckman Coulter
- BTNX, Inc.
- Corolina Liquid Chemistries
- Chromsystems, Inc.
- Co-Innovation Biotech Co., Ltd.
- Confirm Biosciences
- Diagnostic Automation/Cortez Diagnostics Inc.
- Diasystems Scandinevia AB
- Germaine Laboratories, Inc.
- Innovative Testing Solution
- Immunostics, Inc.
- Medacx Ltd.
- Meridian Healthcare srl
- Mossman Associates
- Neogen Corporation
- Orasure Technologies, Inc.
- Pharmatech, Inc.
- Premier Biotech
- Prospectol
- Sekisui Diagnostics
- Siemens Healthineers
- Thermo Fisher Scientific, Inc.